Pa June 11, Kelun-Biotech adalengeza kuti kampani yake yopanga mankhwala a TROP2 ADC sac-TMT (佳泰莱) payokha, pamodzi ndi PD-L1 monoclonal antibody tagitanlimab (科泰莱), yapatsidwa Breakthrough Therapy Designation (BTD) ndi Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) ya ku China kuti ipereke chithandizo choyamba kwa odwala omwe ali ndi khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC) omwe alibe kusintha kwa majini.
Sac-TMT, chinthu chachikulu chomwe Kampaniyo imapanga, ndi TROP2 ADC yatsopano ya anthu yomwe Kampaniyo ili ndi ufulu waumwini wazinthu zanzeru, zomwe zimayang'ana kwambiri zotupa zolimba monga NSCLC, khansa ya m'mawere (BC), khansa ya m'mimba (GC), zotupa za amayi, pakati pa zina. Sac-TMT imapangidwa ndi cholumikizira chatsopano kuti igwirizane ndi katundu wolipira, choletsa topoisomerase I chochokera ku belotecan chokhala ndi chiŵerengero cha mankhwala-mpaka-antibody (DAR) cha 7.4. Sac-TMT imazindikira makamaka TROP2 pamwamba pa maselo a chotupa ndi ma antibodies a monoclonal opangidwa ndi recombinant anti-TROP2, omwe kenako amachotsedwa ndi maselo a chotupa ndikutulutsa KL610023 mkati mwa maselo. KL610023, monga choletsa topoisomerase I, imayambitsa kuwonongeka kwa DNA kwa maselo a chotupa, zomwe zimapangitsa kuti maselo asamayende bwino komanso kuti apoptosis ichitike. Kuphatikiza apo, imatulutsanso KL610023 m'malo ozungulira chotupa. Popeza KL610023 imatha kulowa mu nembanemba, imatha kuyambitsa zotsatira zowoneka ngati munthu akuyang'ana, kapena mwa kuyankhula kwina kupha maselo otupa omwe ali pafupi.
Kusankhidwa kwa Njira Yopangira Matenda Opatsirana kumeneku kumachokera pa deta yogwira ntchito bwino komanso yotetezeka kuchokera ku gulu losakhala la squamous la kafukufuku wa Phase II OptiTROP-Lung01.
Zotsatira za kafukufuku wa OptiTROP-Lung01 Phase II, kuwunika sac-TMT pamodzi ndi KL-A167 (anti-PD-L1 monoclonal antibody) ngati chithandizo choyamba cha odwala a NSCLC omwe alibe majini oyendetsera galimoto, zidaperekedwa pa Msonkhano Wapachaka wa CSCO Academic wa 2024.
Zomwe zapezeka zasonyeza kuti: Pa gulu la 1A, kutsata kwapakati kunali miyezi 14.0, ndi chiŵerengero choyankha mopanda tsankho (ORR) cha 48.6% (18/37, milandu iwiri ikudikira kutsimikizika), chiŵerengero chowongolera matenda (DCR) cha 94.6%, kupulumuka kwapakati kosapitirira (PFS) kwa miyezi 15.4 (95% CI: 6.7, NE), ndi chiŵerengero cha PFS cha miyezi 6 cha 69.2%; pa gulu la 1B, kutsata kwapakati kunali miyezi 6.9, ndi ORR ya 77.6% (45/58, milandu 5 ikudikira kutsimikiziridwa), DCR ya 100.0%, PFS yapakati sinafikebe, ndi PFS ya miyezi 6 ya 84.6%.
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Email：myimmnet@163.com
Nthawi yotumizira: Juni-12-2025